At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 67 enrolled
Drug / intervention
Lipoic acid and fish oil concentrate +1 moredrug
Likely dose
Lipoic acid and fish oil concentrate 600 milligramsfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Lipoic Acid and Omega-3 Fatty Acids in Alzheimer's Disease
In Brief
A Phase 2 clinical trial evaluating Lipoic acid and fish oil concentrate and Placebo for Alzheimer's Disease. Completed, enrolled 67 participants across 1 site.
Detailed Summary
The purpose of this study was to see if taking lipoic acid plus omega-3 fatty acids (omega-3s) can slow the Alzheimer's disease (AD) process. To see if the treatment can slow the AD process, the investigators looked at changes in memory and changes in a person's daily activities over 18 months.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlzheimer's Disease
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedJan 2010
Enrollment StartSep 2010
Primary CompletionDec 2014
TodayJul 2026
First PostedJan 29, 2010
Enrollment StartSep 1, 2010
Primary CompletionDec 1, 2014
TodayJul 2, 2026
Enrollment to primary: 4.3 yearsPosted 16.4 years ago
Interventions
Lipoic acid and fish oil concentratedrug
Lipoic acid (600 milligrams per day) and fish oil concentrate (3 grams per day) for 18 months
Placebodrug
Placebo LA and placebo oil capsules for 18 months